IQVIA Holdings Inc. (NYSE:IQV) Given Average Rating of “Moderate Buy” by Analysts

Shares of IQVIA Holdings Inc. (NYSE:IQV) have been assigned a consensus recommendation of “Moderate Buy” from the twenty-one analysts that are covering the firm, MarketBeat.com reports. Three research analysts have rated the stock with a hold recommendation, seventeen have given a buy recommendation and one has given a strong buy recommendation to the company. The average 12-month target price among analysts that have covered the stock in the last year is $255.82.

Several equities analysts have commented on the company. BTIG Research lowered their price objective on IQVIA from $290.00 to $260.00 and set a “buy” rating for the company in a research report on Friday, November 1st. Deutsche Bank Aktiengesellschaft dropped their price objective on shares of IQVIA from $270.00 to $265.00 and set a “buy” rating on the stock in a research note on Friday, November 1st. Leerink Partners reiterated an “outperform” rating and set a $248.00 target price (down from $260.00) on shares of IQVIA in a report on Tuesday, November 19th. Royal Bank of Canada reaffirmed an “outperform” rating and set a $270.00 price objective on shares of IQVIA in a research report on Wednesday, December 11th. Finally, JPMorgan Chase & Co. dropped their target price on IQVIA from $279.00 to $240.00 and set an “overweight” rating on the stock in a report on Tuesday, November 5th.

IQVIA Stock Up 1.7 %

Shares of NYSE:IQV opened at $202.63 on Wednesday. The company has a debt-to-equity ratio of 1.76, a quick ratio of 0.81 and a current ratio of 0.81. IQVIA has a 52-week low of $187.62 and a 52-week high of $261.73. The firm has a market capitalization of $36.78 billion, a P/E ratio of 26.59, a P/E/G ratio of 2.05 and a beta of 1.48. The stock has a 50 day moving average price of $202.22 and a 200-day moving average price of $221.94.

Institutional Investors Weigh In On IQVIA

Several hedge funds and other institutional investors have recently modified their holdings of IQV. FMR LLC raised its stake in shares of IQVIA by 38.7% in the third quarter. FMR LLC now owns 2,887,342 shares of the medical research company’s stock worth $684,213,000 after buying an additional 804,963 shares during the period. B. Metzler seel. Sohn & Co. Holding AG bought a new stake in IQVIA during the third quarter valued at about $147,683,000. JPMorgan Chase & Co. lifted its holdings in shares of IQVIA by 46.2% in the third quarter. JPMorgan Chase & Co. now owns 1,845,711 shares of the medical research company’s stock worth $437,378,000 after buying an additional 583,396 shares in the last quarter. Nordea Investment Management AB grew its position in shares of IQVIA by 47.4% during the fourth quarter. Nordea Investment Management AB now owns 1,405,281 shares of the medical research company’s stock valued at $277,908,000 after purchasing an additional 452,029 shares in the last quarter. Finally, 1832 Asset Management L.P. increased its stake in IQVIA by 472.3% in the 2nd quarter. 1832 Asset Management L.P. now owns 456,335 shares of the medical research company’s stock worth $96,487,000 after acquiring an additional 376,595 shares during the last quarter. 89.62% of the stock is currently owned by hedge funds and other institutional investors.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.